Posted by Michael Wonder on 09 Apr 2019
Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy
9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public meeting also being accepted.
BOSTON, April 9, 2019 - The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the clinical effectiveness and value of two new technologies to induce immune tolerance -- Viaskin Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) -- as well as non-commercialised oral immunotherapy (OIT).
This draft report will be open to public comment until 5 pm ET on 8 May 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on May 28, 2019. The Evidence Report will be subject to deliberation during a public meeting of the California Technology Assessment Forum, one of ICER's three independent evidence appraisal committees, on 11 June 2019.
